NASDAQ:VCYT Veracyte Q3 2026 Earnings Report $43.16 -1.49 (-3.34%) Closing price 10/7/2026 04:00 PM EasternExtended Trading$43.38 +0.22 (+0.52%) As of 10/7/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Veracyte EPS ResultsActual EPSN/AConsensus EPS $0.43Beat/MissN/AOne Year Ago EPSN/AVeracyte Revenue ResultsActual RevenueN/AExpected Revenue$147.16 millionBeat/MissN/AYoY Revenue GrowthN/AVeracyte Announcement DetailsQuarterQ3 2026Date11/3/2026TimeAfter Market ClosesConference Call DateTuesday, November 3, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Veracyte Earnings HeadlinesVeracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026October 2, 2026 | finance.yahoo.comVeracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III DataOctober 2, 2026 | finance.yahoo.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production. | Golden Portfolio (Ad)Could Veracyte (VCYT) Change Prostate Cancer Care With New Phase III Data?October 1, 2026 | finance.yahoo.comVeracyte, Inc. Reports NRG/RTOG 0815 Analysis Shows Decipher Prostate Genomic Classifier Predicts Benefit From Adding Short-Term Androgen Deprivation Therapy To Dose-Escalated ...September 29, 2026 | marketscreener.comMVeracyte's Decipher Test Predicts Hormone Therapy Benefit In Phase 3 Prostate Cancer AnalysisSeptember 29, 2026 | rttnews.comSee More Veracyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Veracyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veracyte and other key companies, straight to your email. Email Address About VeracyteVeracyte (NASDAQ:VCYT) is a diagnostic company that develops and commercializes genomic tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. Its tests analyze genetic information from patient samples and are intended to provide more precise answers than traditional diagnostic methods alone. The company’s portfolio includes Afirma genomic tests for thyroid nodules, Decipher tests for prostate cancer, Percepta tests for lung cancer and Envisio tests that support the evaluation of certain lung nodules. Veracyte also offers CancerTYPE ID, a molecular test designed to help identify the tissue of origin for difficult-to-diagnose cancers. The company expanded its capabilities in spatial biology and breast cancer testing through its acquisition of NanoString Technologies, which added products including the Prosigna breast cancer assay and spatial biology platforms. Founded in 2008 and headquartered in South San Francisco, California, Veracyte serves healthcare providers, laboratories and patients primarily in the United States, with certain products and services available internationally through regulatory approvals and commercial relationships. The company is led by President and Chief Executive Officer Marc Stapley.View Veracyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
